Kluyvera cryocrescens, initially isolated from soil in 1936, have been found in various sources, including water, plants, animals, and humans. It is classified as an opportunistic pathogen capable of causing infections, particularly in immunocompromised individuals or those with underlying conditions like diabetes, cancer, or renal failure. The most common clinical presentations associated with Kluyvera cryocrescens infections are urinary tract infections, bacteremia, wound infections, and meningitis.
The exact prevalence of Kluyvera cryocrescens in different regions worldwide remains uncertain, mainly because it is frequently misidentified as other Enterobacteriaceae due to its relatively low virulence. Nonetheless, several studies have reported its isolation from clinical and environmental samples in various countries, including India, China, Brazil, Spain, and the United States.
The incidence of Kluyvera cryocrescens infections is estimated to be very low when compared to more common pathogens. For instance, a study in Spain revealed that K. cryocrescens accounted for a mere 0.03% of all Enterobacteriaceae isolates from blood cultures between 2000 and 2010. Since its first isolation from human clinical specimens in 1976, approximately 100 cases have been documented globally, with a predominant occurrence in Europe and North America and sporadic cases in Asia, Africa, andSouth America.
The prevalence of Kluyvera cryocrescens in the environment or within the normal flora of humans and animals remains largely unknown but is presumed to be low based on available data. Studies from India and Brazil found K. cryocrescens in just a small percentage of clinical and stool samples, respectively. Notably, there have been no reports of endemic outbreaks associated with K. cryocrescens infection.
However, some cases have been linked to nosocomial transmission or exposure to contaminated medical devices or water sources. Risk factors for acquiring K. cryocrescens infection include conditions that weaken the immune system, such as immunosuppression, malignancy, diabetes, renal failure, and factors like surgery, trauma, catheterization, dialysis, and antibiotic use.
Classification and Structure:
Kingdom: Bacteria
Phylum: Pseudomonadota
Class: Gammaproteobacteria
Order: Enterobacterales
Family: Enterobacteriaceae
Genus:Kluyvera
Species:K. cryocrescens
Kluyvera cryocrescens is a gram-negative bacterium characterized by its rod-shaped morphology and peritrichous flagella, enabling motility.
Regarding size, K. cryocrescens typically have an average length ranging from 1 to 5 μm and a diameter falling within the range of 0.5 to 1.5 μm.
This bacterium exhibits growth on MacConkey agar and can ferment glucose. Additionally, it can utilize citrate and malonate as carbon sources, decarboxylate lysine, and ornithine, and is known to produce substantial quantities of α-ketoglutaric acid.
Kluyvera cryocrescens possesses several virulent factors and mechanisms that contribute to its pathogenicity. One significant virulence factor is the production of beta-lactamases, enzymes capable of breaking down beta-lactam antibiotics, including penicillins and cephalosporins. Among these, K. cryocrescens can produce KLUC-2, a chromosomal class C cephalosporinase, and NDM-1, a plasmid mediated metallo-beta-lactamase known for its ability to hydrolyze carbapenem antibiotics, rendering resistance.
Additionally, Kluyvera cryocrescens employs metabolic pathways for citrate and malonate utilization, enabling it to use these compounds as carbon sources, which can be advantageous in nutrient-limited environments. Furthermore, Kluyvera cryocrescens can produce α-ketoglutaric acid through a specific biochemical reaction, potentially in acid tolerance or virulence modulation.
Regarding specific strains, the type strain of Kluyvera cryocrescens, K. cryocrescens 12993, was initially isolated from a clinical specimen in 1976. It has been deposited in various culture collections, including ATCC, CCUG, CDC, CIP, DSM, JCM, LMG, and NBRC, making it accessible for research and reference.
Another notable strain is K. cryocrescens NDM-1, recognized for producing the metallo-beta-lactamase NDM-1. This strain was isolated from a patient with a urinary tract infection in India in 2009 and exhibited resistance to multiple antibiotics, particularly carbapenems.
Kluyveracryocrescens can inhabit various human tracts as a commensal organism but may turn pathogenic under specific conditions. The precise mechanisms underlying its pathogenesis remain unclear.
Still, it is reportedly associated with its capacity to produce beta-lactamases, which are enzymes capable of breaking down certain antibiotics. This potentially virulent pathogen requires aggressive treatment with appropriate antibiotics to combat infections effectively.
Human host defenses against Kluyvera cryocrescens involve a multifaceted approach to prevent or control infection. The body’s innate immune system comprises physical barriers, like the skin & mucous membranes, which serve as the first line of defense. Chemical mediators like lysozyme and the complement system, along with cellular components including neutrophils, macrophages, and natural killer cells, are crucial in recognizing and eliminating foreign invaders.
In the adaptive immune system, lymphocytes, specifically T and B cells, play a significant role. These cells possess the ability for specific recognition and memory of antigens, such as bacterial proteins or polysaccharides. B cells can produce antibodies, while T cells can release cytotoxic molecules, both targeting and neutralizing or destroying the bacteria or infected cells.
These mechanisms are pivotal in the adaptive immune system’s ability to mount a specific and long-lasting response against Kluyvera cryocrescens.Another critical component in host defenses is the presence of the normal flora, beneficial microorganisms that naturally colonize the human body. These microbes compete with potential pathogens for nutrients and space, helping to prevent infections.
In cases where antimicrobial therapy is required, certain drugs can inhibit or kill K. cryocrescens by interfering with various bacterial processes, such as cell wall synthesis, protein synthesis, DNA replication, or metabolic pathways. However, the bacterium’s ability to acquire resistance genes from other bacteria poses a challenge, leading to multidrug resistance. Antimicrobial agents effective against most K. cryocrescens strains include third-generation cephalosporins, aminoglycosides, cefepime, piperacillin-tazobactam, and carbapenems.
Kluyvera cryocrescens, a bacterium, is known to cause human infections, notably in individuals with compromised immunity or hospitalized. The clinical manifestations of Kluyvera cryocrescens infections commonly include:
Urinary Tract Infections (UTIs): UTIs are a joint clinical presentation, leading to symptoms such as frequent urination, a burning sensation during urination, and sometimes blood in the urine.
Bacteremia:Kluyvera cryocrescens can enter the bloodstream, causing bacteremia. This condition may result in fever, chills, and general discomfort.
Meningitis: Although less common, Kluyvera cryocrescens infections can lead to meningitis, a serious condition characterized by neck stiffness, severe headache, and neurological changes.
Other Symptoms: Some individuals infected with Kluyvera cryocrescens may experience additional symptoms like fever, dyspnea (shortness of breath), cough, nausea, thrombocytopenia (low platelet count), and hypoglycemia (low blood sugar).
Diagnosing Kluyvera cryocrescens infection typically involves isolating and identifying the organism from clinical specimens like urine, blood, or tissue samples. Several methods can be employed for accurate identification:
VITEK® 2 System: This automated system utilizes biochemical tests and fluorescence detection to identify bacteria and assess their antimicrobial susceptibility. It aids in rapid and precise identification.
Matrix-Assisted Laser Ionization/Desorption Time-of-Flight Mass Spectrometry (MALDI-TOF MS): MALDI-TOF MS is a sophisticated technique that employs laser ionization of bacterial proteins, measuring their mass-to-charge ratio to generate a unique fingerprint for each species, facilitating reliable identification.
16S rRNA Sequencing: A molecular approach, 16S rRNA sequencing involves amplifying and sequencing a specific bacterial ribosomal RNA gene region. This sequence can be compared with reference databases to identify the species, providing a robust diagnostic tool accurately.
Preventive measures against Kluyvera cryocrescens include practicing good hygiene, with frequent and proper handwashing, especially before and after using the toilet, handling food, or touching medical devices.
Additionally, avoiding contact with contaminated water sources or medical devices, such as catheters, dialysis machines, or endoscopes, is essential to reduce the risk of infection.
If symptoms of infection, such as fever, pain, burning sensation during urination, or pus discharge from wounds, occur, seeking prompt medical attention is crucial. Following the prescribed antimicrobial therapy based on susceptibility testing and completing the entire course of treatment is vital to ensure effective treatment and prevent the development of antibiotic resistance.
Kluyvera cryocrescens, initially isolated from soil in 1936, have been found in various sources, including water, plants, animals, and humans. It is classified as an opportunistic pathogen capable of causing infections, particularly in immunocompromised individuals or those with underlying conditions like diabetes, cancer, or renal failure. The most common clinical presentations associated with Kluyvera cryocrescens infections are urinary tract infections, bacteremia, wound infections, and meningitis.
The exact prevalence of Kluyvera cryocrescens in different regions worldwide remains uncertain, mainly because it is frequently misidentified as other Enterobacteriaceae due to its relatively low virulence. Nonetheless, several studies have reported its isolation from clinical and environmental samples in various countries, including India, China, Brazil, Spain, and the United States.
The incidence of Kluyvera cryocrescens infections is estimated to be very low when compared to more common pathogens. For instance, a study in Spain revealed that K. cryocrescens accounted for a mere 0.03% of all Enterobacteriaceae isolates from blood cultures between 2000 and 2010. Since its first isolation from human clinical specimens in 1976, approximately 100 cases have been documented globally, with a predominant occurrence in Europe and North America and sporadic cases in Asia, Africa, andSouth America.
The prevalence of Kluyvera cryocrescens in the environment or within the normal flora of humans and animals remains largely unknown but is presumed to be low based on available data. Studies from India and Brazil found K. cryocrescens in just a small percentage of clinical and stool samples, respectively. Notably, there have been no reports of endemic outbreaks associated with K. cryocrescens infection.
However, some cases have been linked to nosocomial transmission or exposure to contaminated medical devices or water sources. Risk factors for acquiring K. cryocrescens infection include conditions that weaken the immune system, such as immunosuppression, malignancy, diabetes, renal failure, and factors like surgery, trauma, catheterization, dialysis, and antibiotic use.
Classification and Structure:
Kingdom: Bacteria
Phylum: Pseudomonadota
Class: Gammaproteobacteria
Order: Enterobacterales
Family: Enterobacteriaceae
Genus:Kluyvera
Species:K. cryocrescens
Kluyvera cryocrescens is a gram-negative bacterium characterized by its rod-shaped morphology and peritrichous flagella, enabling motility.
Regarding size, K. cryocrescens typically have an average length ranging from 1 to 5 μm and a diameter falling within the range of 0.5 to 1.5 μm.
This bacterium exhibits growth on MacConkey agar and can ferment glucose. Additionally, it can utilize citrate and malonate as carbon sources, decarboxylate lysine, and ornithine, and is known to produce substantial quantities of α-ketoglutaric acid.
Kluyvera cryocrescens possesses several virulent factors and mechanisms that contribute to its pathogenicity. One significant virulence factor is the production of beta-lactamases, enzymes capable of breaking down beta-lactam antibiotics, including penicillins and cephalosporins. Among these, K. cryocrescens can produce KLUC-2, a chromosomal class C cephalosporinase, and NDM-1, a plasmid mediated metallo-beta-lactamase known for its ability to hydrolyze carbapenem antibiotics, rendering resistance.
Additionally, Kluyvera cryocrescens employs metabolic pathways for citrate and malonate utilization, enabling it to use these compounds as carbon sources, which can be advantageous in nutrient-limited environments. Furthermore, Kluyvera cryocrescens can produce α-ketoglutaric acid through a specific biochemical reaction, potentially in acid tolerance or virulence modulation.
Regarding specific strains, the type strain of Kluyvera cryocrescens, K. cryocrescens 12993, was initially isolated from a clinical specimen in 1976. It has been deposited in various culture collections, including ATCC, CCUG, CDC, CIP, DSM, JCM, LMG, and NBRC, making it accessible for research and reference.
Another notable strain is K. cryocrescens NDM-1, recognized for producing the metallo-beta-lactamase NDM-1. This strain was isolated from a patient with a urinary tract infection in India in 2009 and exhibited resistance to multiple antibiotics, particularly carbapenems.
Kluyveracryocrescens can inhabit various human tracts as a commensal organism but may turn pathogenic under specific conditions. The precise mechanisms underlying its pathogenesis remain unclear.
Still, it is reportedly associated with its capacity to produce beta-lactamases, which are enzymes capable of breaking down certain antibiotics. This potentially virulent pathogen requires aggressive treatment with appropriate antibiotics to combat infections effectively.
Human host defenses against Kluyvera cryocrescens involve a multifaceted approach to prevent or control infection. The body’s innate immune system comprises physical barriers, like the skin & mucous membranes, which serve as the first line of defense. Chemical mediators like lysozyme and the complement system, along with cellular components including neutrophils, macrophages, and natural killer cells, are crucial in recognizing and eliminating foreign invaders.
In the adaptive immune system, lymphocytes, specifically T and B cells, play a significant role. These cells possess the ability for specific recognition and memory of antigens, such as bacterial proteins or polysaccharides. B cells can produce antibodies, while T cells can release cytotoxic molecules, both targeting and neutralizing or destroying the bacteria or infected cells.
These mechanisms are pivotal in the adaptive immune system’s ability to mount a specific and long-lasting response against Kluyvera cryocrescens.Another critical component in host defenses is the presence of the normal flora, beneficial microorganisms that naturally colonize the human body. These microbes compete with potential pathogens for nutrients and space, helping to prevent infections.
In cases where antimicrobial therapy is required, certain drugs can inhibit or kill K. cryocrescens by interfering with various bacterial processes, such as cell wall synthesis, protein synthesis, DNA replication, or metabolic pathways. However, the bacterium’s ability to acquire resistance genes from other bacteria poses a challenge, leading to multidrug resistance. Antimicrobial agents effective against most K. cryocrescens strains include third-generation cephalosporins, aminoglycosides, cefepime, piperacillin-tazobactam, and carbapenems.
Kluyvera cryocrescens, a bacterium, is known to cause human infections, notably in individuals with compromised immunity or hospitalized. The clinical manifestations of Kluyvera cryocrescens infections commonly include:
Urinary Tract Infections (UTIs): UTIs are a joint clinical presentation, leading to symptoms such as frequent urination, a burning sensation during urination, and sometimes blood in the urine.
Bacteremia:Kluyvera cryocrescens can enter the bloodstream, causing bacteremia. This condition may result in fever, chills, and general discomfort.
Meningitis: Although less common, Kluyvera cryocrescens infections can lead to meningitis, a serious condition characterized by neck stiffness, severe headache, and neurological changes.
Other Symptoms: Some individuals infected with Kluyvera cryocrescens may experience additional symptoms like fever, dyspnea (shortness of breath), cough, nausea, thrombocytopenia (low platelet count), and hypoglycemia (low blood sugar).
Diagnosing Kluyvera cryocrescens infection typically involves isolating and identifying the organism from clinical specimens like urine, blood, or tissue samples. Several methods can be employed for accurate identification:
VITEK® 2 System: This automated system utilizes biochemical tests and fluorescence detection to identify bacteria and assess their antimicrobial susceptibility. It aids in rapid and precise identification.
Matrix-Assisted Laser Ionization/Desorption Time-of-Flight Mass Spectrometry (MALDI-TOF MS): MALDI-TOF MS is a sophisticated technique that employs laser ionization of bacterial proteins, measuring their mass-to-charge ratio to generate a unique fingerprint for each species, facilitating reliable identification.
16S rRNA Sequencing: A molecular approach, 16S rRNA sequencing involves amplifying and sequencing a specific bacterial ribosomal RNA gene region. This sequence can be compared with reference databases to identify the species, providing a robust diagnostic tool accurately.
Preventive measures against Kluyvera cryocrescens include practicing good hygiene, with frequent and proper handwashing, especially before and after using the toilet, handling food, or touching medical devices.
Additionally, avoiding contact with contaminated water sources or medical devices, such as catheters, dialysis machines, or endoscopes, is essential to reduce the risk of infection.
If symptoms of infection, such as fever, pain, burning sensation during urination, or pus discharge from wounds, occur, seeking prompt medical attention is crucial. Following the prescribed antimicrobial therapy based on susceptibility testing and completing the entire course of treatment is vital to ensure effective treatment and prevent the development of antibiotic resistance.
Kluyvera cryocrescens, initially isolated from soil in 1936, have been found in various sources, including water, plants, animals, and humans. It is classified as an opportunistic pathogen capable of causing infections, particularly in immunocompromised individuals or those with underlying conditions like diabetes, cancer, or renal failure. The most common clinical presentations associated with Kluyvera cryocrescens infections are urinary tract infections, bacteremia, wound infections, and meningitis.
The exact prevalence of Kluyvera cryocrescens in different regions worldwide remains uncertain, mainly because it is frequently misidentified as other Enterobacteriaceae due to its relatively low virulence. Nonetheless, several studies have reported its isolation from clinical and environmental samples in various countries, including India, China, Brazil, Spain, and the United States.
The incidence of Kluyvera cryocrescens infections is estimated to be very low when compared to more common pathogens. For instance, a study in Spain revealed that K. cryocrescens accounted for a mere 0.03% of all Enterobacteriaceae isolates from blood cultures between 2000 and 2010. Since its first isolation from human clinical specimens in 1976, approximately 100 cases have been documented globally, with a predominant occurrence in Europe and North America and sporadic cases in Asia, Africa, andSouth America.
The prevalence of Kluyvera cryocrescens in the environment or within the normal flora of humans and animals remains largely unknown but is presumed to be low based on available data. Studies from India and Brazil found K. cryocrescens in just a small percentage of clinical and stool samples, respectively. Notably, there have been no reports of endemic outbreaks associated with K. cryocrescens infection.
However, some cases have been linked to nosocomial transmission or exposure to contaminated medical devices or water sources. Risk factors for acquiring K. cryocrescens infection include conditions that weaken the immune system, such as immunosuppression, malignancy, diabetes, renal failure, and factors like surgery, trauma, catheterization, dialysis, and antibiotic use.
Classification and Structure:
Kingdom: Bacteria
Phylum: Pseudomonadota
Class: Gammaproteobacteria
Order: Enterobacterales
Family: Enterobacteriaceae
Genus:Kluyvera
Species:K. cryocrescens
Kluyvera cryocrescens is a gram-negative bacterium characterized by its rod-shaped morphology and peritrichous flagella, enabling motility.
Regarding size, K. cryocrescens typically have an average length ranging from 1 to 5 μm and a diameter falling within the range of 0.5 to 1.5 μm.
This bacterium exhibits growth on MacConkey agar and can ferment glucose. Additionally, it can utilize citrate and malonate as carbon sources, decarboxylate lysine, and ornithine, and is known to produce substantial quantities of α-ketoglutaric acid.
Kluyvera cryocrescens possesses several virulent factors and mechanisms that contribute to its pathogenicity. One significant virulence factor is the production of beta-lactamases, enzymes capable of breaking down beta-lactam antibiotics, including penicillins and cephalosporins. Among these, K. cryocrescens can produce KLUC-2, a chromosomal class C cephalosporinase, and NDM-1, a plasmid mediated metallo-beta-lactamase known for its ability to hydrolyze carbapenem antibiotics, rendering resistance.
Additionally, Kluyvera cryocrescens employs metabolic pathways for citrate and malonate utilization, enabling it to use these compounds as carbon sources, which can be advantageous in nutrient-limited environments. Furthermore, Kluyvera cryocrescens can produce α-ketoglutaric acid through a specific biochemical reaction, potentially in acid tolerance or virulence modulation.
Regarding specific strains, the type strain of Kluyvera cryocrescens, K. cryocrescens 12993, was initially isolated from a clinical specimen in 1976. It has been deposited in various culture collections, including ATCC, CCUG, CDC, CIP, DSM, JCM, LMG, and NBRC, making it accessible for research and reference.
Another notable strain is K. cryocrescens NDM-1, recognized for producing the metallo-beta-lactamase NDM-1. This strain was isolated from a patient with a urinary tract infection in India in 2009 and exhibited resistance to multiple antibiotics, particularly carbapenems.
Kluyveracryocrescens can inhabit various human tracts as a commensal organism but may turn pathogenic under specific conditions. The precise mechanisms underlying its pathogenesis remain unclear.
Still, it is reportedly associated with its capacity to produce beta-lactamases, which are enzymes capable of breaking down certain antibiotics. This potentially virulent pathogen requires aggressive treatment with appropriate antibiotics to combat infections effectively.
Human host defenses against Kluyvera cryocrescens involve a multifaceted approach to prevent or control infection. The body’s innate immune system comprises physical barriers, like the skin & mucous membranes, which serve as the first line of defense. Chemical mediators like lysozyme and the complement system, along with cellular components including neutrophils, macrophages, and natural killer cells, are crucial in recognizing and eliminating foreign invaders.
In the adaptive immune system, lymphocytes, specifically T and B cells, play a significant role. These cells possess the ability for specific recognition and memory of antigens, such as bacterial proteins or polysaccharides. B cells can produce antibodies, while T cells can release cytotoxic molecules, both targeting and neutralizing or destroying the bacteria or infected cells.
These mechanisms are pivotal in the adaptive immune system’s ability to mount a specific and long-lasting response against Kluyvera cryocrescens.Another critical component in host defenses is the presence of the normal flora, beneficial microorganisms that naturally colonize the human body. These microbes compete with potential pathogens for nutrients and space, helping to prevent infections.
In cases where antimicrobial therapy is required, certain drugs can inhibit or kill K. cryocrescens by interfering with various bacterial processes, such as cell wall synthesis, protein synthesis, DNA replication, or metabolic pathways. However, the bacterium’s ability to acquire resistance genes from other bacteria poses a challenge, leading to multidrug resistance. Antimicrobial agents effective against most K. cryocrescens strains include third-generation cephalosporins, aminoglycosides, cefepime, piperacillin-tazobactam, and carbapenems.
Kluyvera cryocrescens, a bacterium, is known to cause human infections, notably in individuals with compromised immunity or hospitalized. The clinical manifestations of Kluyvera cryocrescens infections commonly include:
Urinary Tract Infections (UTIs): UTIs are a joint clinical presentation, leading to symptoms such as frequent urination, a burning sensation during urination, and sometimes blood in the urine.
Bacteremia:Kluyvera cryocrescens can enter the bloodstream, causing bacteremia. This condition may result in fever, chills, and general discomfort.
Meningitis: Although less common, Kluyvera cryocrescens infections can lead to meningitis, a serious condition characterized by neck stiffness, severe headache, and neurological changes.
Other Symptoms: Some individuals infected with Kluyvera cryocrescens may experience additional symptoms like fever, dyspnea (shortness of breath), cough, nausea, thrombocytopenia (low platelet count), and hypoglycemia (low blood sugar).
Diagnosing Kluyvera cryocrescens infection typically involves isolating and identifying the organism from clinical specimens like urine, blood, or tissue samples. Several methods can be employed for accurate identification:
VITEK® 2 System: This automated system utilizes biochemical tests and fluorescence detection to identify bacteria and assess their antimicrobial susceptibility. It aids in rapid and precise identification.
Matrix-Assisted Laser Ionization/Desorption Time-of-Flight Mass Spectrometry (MALDI-TOF MS): MALDI-TOF MS is a sophisticated technique that employs laser ionization of bacterial proteins, measuring their mass-to-charge ratio to generate a unique fingerprint for each species, facilitating reliable identification.
16S rRNA Sequencing: A molecular approach, 16S rRNA sequencing involves amplifying and sequencing a specific bacterial ribosomal RNA gene region. This sequence can be compared with reference databases to identify the species, providing a robust diagnostic tool accurately.
Preventive measures against Kluyvera cryocrescens include practicing good hygiene, with frequent and proper handwashing, especially before and after using the toilet, handling food, or touching medical devices.
Additionally, avoiding contact with contaminated water sources or medical devices, such as catheters, dialysis machines, or endoscopes, is essential to reduce the risk of infection.
If symptoms of infection, such as fever, pain, burning sensation during urination, or pus discharge from wounds, occur, seeking prompt medical attention is crucial. Following the prescribed antimicrobial therapy based on susceptibility testing and completing the entire course of treatment is vital to ensure effective treatment and prevent the development of antibiotic resistance.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
